USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
AMERICAN LIFE SCIENCE PHARMACEUTICALS
Address:
AMERICAN LIFE SCIENCE PHARMACEUTICALS, INC.
3030 Bunker Hill St.
SAN DIEGO, CA 92109
Phone:
N/A
URL:
N/A
EIN:
680513217
DUNS:
170560960
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
Yes

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $367,776.00 3
SBIR Phase II $3,834,808.00 3

Award List:

Drugs to Elevate Enkephalin as Novel Opiate Analgesics

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$157,550.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Pain is a serious, debilitating condition that is under-treated because of the dose-limiting side effects of currently used opiate drugs such as morphine. Enkephalin is an endogenous opiate peptide, which induces analgesia, but unlike morphine it has few, if any… More

Gamma Secretase Assays to Discover Drugs for Alzheimer's

Award Year / Program / Phase:
2005 / SBIR / Phase II
Award Amount:
$1,541,516.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is a long-term, debilitating disorder that causes loss of memory and cognitive functions. There is an urgent need for effective therapeutic agents to ameliorate the symptoms of AD. Important molecular drug targets in AD are the… More

Development of E64d for Alzheimer's disease

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$115,137.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): There currently is no drug available that stops the progression of Alzheimer's disease (AD). The abnormal accumulation of neurotoxic brain ss-amyloid peptides (A?) is thought to be a possible cause the disease. A? are p roduced by proteolytic cleavage of a larger… More

Development of protease inhibitor drugs to treat Alzheimer's disease

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$95,089.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): There currently is no drug available that stops the progression of Alzheimer's disease (AD). Neurotoxic ?-amyloid peptides (A??) are thought to cause the disease with their accumulation in brain plaques being a hallmar k. A? are cleaved from a larger amyloid… More

Development of protease inhibitor drugs to treat Alzheimer's disease

Award Year / Program / Phase:
2009 / SBIR / Phase II
Award Amount:
$1,144,772.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

Development of E64d for Alzheimer's disease

Award Year / Program / Phase:
2009 / SBIR / Phase II
Award Amount:
$1,148,520.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a